Outcomes after unilateral bevacizumab treatment for infants with asymmetric retinopathy of prematurity

Daniel G Nelson; G Baker Hubbard; Amy K Hutchinson

doi:10.1016/j.jaapos.2024.104091

Outcomes after unilateral bevacizumab treatment for infants with asymmetric retinopathy of prematurity

J AAPOS. 2024 Dec 27:104091. doi: 10.1016/j.jaapos.2024.104091. Online ahead of print.

Authors

Daniel G Nelson¹, G Baker Hubbard², Amy K Hutchinson²

Affiliations

¹ Department of Ophthalmology, Emory University, Atlanta, Georgia. Electronic address: Daniel.nelson2@ochsner.org.
² Department of Ophthalmology, Emory University, Atlanta, Georgia.

PMID: 39733909
DOI: 10.1016/j.jaapos.2024.104091

Abstract

In this retrospective study of asymmetric retinopathy of prematurity (ROP) cases treated with unilateral intravitreal bevacizumab (IVB), half of the treated patients did not require further IVB, whereas the other half required sequential IVB at a mean of 12 days after initial treatment.

Publication types

Case Reports